A cancer treatment denial occurs when an insurance company refuses to pay for a recommended cancer therapy, forcing patients to either forgo potentially life-saving treatment, pay out of pocket, or delay care while pursuing appeals. According to the American Cancer Society’s 2024 Access to Care Report, 34% of cancer patients experience at least one treatment denial during their care journey—a staggering figure that reveals how widespread this problem has become across the U.S. healthcare system. When insurers deny coverage for oncology treatments, patients face not only the emotional and financial burden of fighting both cancer and their insurance company, but also critical medical consequences.
The timing of these denials can be devastating. Research from the Journal of Clinical Oncology’s Patient Impact Study shows that the average treatment delay when insurance denies cancer treatment is 27 days—a critical window during which aggressive cancers can progress significantly. For some patients, this delay can mean the difference between treatable disease and advanced cancer. Patients have pursued legal action against insurers, filed class action lawsuits, and sought regulatory intervention to challenge systematic denial patterns. Understanding cancer treatment denials, why they happen, and what legal recourse exists is essential for patients navigating the intersection of oncology and insurance coverage.
Table of Contents
- Why Do Insurance Companies Deny Cancer Treatment Coverage?
- The Disproportionate Impact on Immunotherapy and Radiation Treatments
- Real-World Example—The Keytruda Access Battle
- Appeal Outcomes and the Independent Medical Review Process
- The Class Action Lawsuit Response to Systematic Denials
- The Genetic Testing Component of Cancer Treatment Denials
- Regulatory and Legislative Responses to Cancer Treatment Denials
- Conclusion
Why Do Insurance Companies Deny Cancer Treatment Coverage?
Insurance companies cite several reasons for denying cancer treatments, most commonly claiming that a therapy is “experimental,” “not medically necessary,” or “off-label” when no FDA-approved alternative exists. However, many denials are contradicted by clinical guidelines from organizations like the National Comprehensive Cancer Network (NCCN) and recommendations from treating oncologists who understand the patient’s specific disease stage and prognosis. Insurance companies may also deny treatments due to cost, applying blanket policies that don’t account for individual patient circumstances or the proven efficacy of newer cancer therapies. The financial incentive structure in health insurance creates misaligned priorities.
Insurers profit when they pay out less in claims, creating pressure to deny or delay expensive treatments—particularly newer immunotherapies and precision medicine approaches that can cost tens of thousands of dollars per month. While insurance companies are legally required to provide coverage for medically necessary care, the definition of “medically necessary” becomes a battleground in cancer treatment disputes. Some insurers deny genetic testing upfront, preventing patients from accessing personalized treatment information that could guide therapy selection. This gatekeeping approach prioritizes short-term cost savings over patient outcomes.
The Disproportionate Impact on Immunotherapy and Radiation Treatments
Immunotherapy treatments, which have revolutionized cancer care for many patients, face a 41% denial rate according to the Association for Community Cancer Centers—making these among the most frequently rejected cancer therapies despite their proven survival benefits. This is particularly troubling because immunotherapy represents a major advancement in treatment options for conditions like melanoma, lung cancer, and certain lymphomas. When insurers deny immunotherapy, they are often blocking access to treatments that clinical evidence shows can extend patient survival and improve quality of life compared to older chemotherapy approaches. Radiation therapy denials have also increased significantly.
Data from a 2024 PubMed study revealed concerning trends: radiation therapy denial rates reached 15.04% in 2022, 18.69% in 2023, and 16.01% in 2024. These rates are significantly higher than the 3.44–5.28% inappropriate denial rate for all health services across other medical specialties. The elevation of cancer-specific denials suggests that oncology treatments face heightened scrutiny or systematic barriers within insurance review processes. For patients with early-stage breast cancer, lung cancer, or other conditions where radiation is standard of care, these denials can force them to delay or skip treatment entirely.
Real-World Example—The Keytruda Access Battle
The struggle to access Keytruda (pembrolizumab), a checkpoint inhibitor immunotherapy, exemplifies how cancer treatment denials play out globally and legally. According to an International Consortium of Investigative Journalists (ICIJ) investigation into cancer drug access, patients in Mexico filed 55 legal motions (amparos) seeking access to Keytruda between October 2017 and February 2026. These legal challenges resulted in 36 decisions granting patients access to the drug.
This case demonstrates that when standard insurance appeal processes fail, patients increasingly turn to litigation as a tool to secure access to treatment that their physicians recommend. The Keytruda cases reveal systemic patterns: patients waited months for access determinations while their cancer progressed, forcing them to seek emergency injunctions and legal intervention. In many instances, the amparos were successful, suggesting that the initial denial decisions were not based on sound medical evidence. This pattern—denials being overturned through legal channels—repeats across cancer treatment disputes in the United States as well, indicating that insurers may be making coverage decisions that don’t withstand scrutiny from independent medical reviewers or courts.
Appeal Outcomes and the Independent Medical Review Process
When patients or their physicians appeal a cancer treatment denial, some insurers are required to undergo an independent medical review (IMR) process where a physician not employed by the insurance company evaluates the medical necessity of the denied treatment. For genetic testing denials specifically, 46% were overturned when appealed through IMR processes between 2019 and 2023. This 46% overturn rate is significant because it demonstrates that a substantial portion of initial denials do not hold up to scrutiny by independent medical professionals, suggesting these denials may have been inappropriate or overly restrictive from the start.
However, a major limitation undermines this potentially positive outcome: less than 1% of denials are actually appealed through the IMR pathway, despite the higher success rates for those who do appeal. This gap exists because many patients and physicians are unaware that the IMR process exists, lack the resources to navigate the complex appeals process, or cannot afford the time delay involved in appealing while their cancer progresses. Some patients choose to pay out of pocket rather than spend weeks appealing, effectively surrendering their right to insurance coverage. This creates a system where the most determined or financially capable patients may eventually access denied treatments, while others suffer treatment delays or go without care.
The Class Action Lawsuit Response to Systematic Denials
As individual denials accumulate into patterns, patients have pursued class action lawsuits against insurers, arguing that systematic denial practices constitute breach of contract, bad faith, and violations of state insurance laws. These lawsuits challenge not just individual cases but the underlying policies and procedures that insurers use to make coverage decisions. Class actions allow patients to collectively challenge practices like automatically denying immunotherapy treatments without individual medical review, or implementing blanket policies that treat advanced cancer patients the same as early-stage patients.
One critical limitation of class action litigation in this space is the length of time required to resolve these cases. A cancer patient may not survive the years required for a class action to move through litigation and settlement, making the legal remedy less meaningful for the individual class member. Additionally, some settlements may result in changes to insurer procedures or monetary compensation, but individual patients must prove they were harmed by the specific practice—a requirement that can be burdensome when a patient’s cancer has already progressed due to treatment delay.
The Genetic Testing Component of Cancer Treatment Denials
Genetic testing for cancer-related mutations (BRCA1/BRCA2, EGFR, microsatellite instability, and others) is increasingly critical for determining the most appropriate treatment, yet insurers frequently deny coverage for this testing upfront. When genetic testing is denied, patients cannot access the information necessary to qualify for targeted therapies or immunotherapies that would otherwise be denied as “not medically necessary.” The 46% overturn rate for genetic testing denials on appeal reveals that insurers are denying access to this foundational diagnostic tool at rates that don’t survive independent medical scrutiny.
A practical example: a patient with advanced lung cancer may be denied EGFR testing because the insurer claims it’s “experimental” or “not standard,” even though EGFR-positive patients have dramatically better outcomes with targeted therapies like erlotinib compared to chemotherapy. The denial of the test effectively denies access to the superior treatment. When patients appeal through independent medical review, nearly half the time the denial is reversed, confirming that the initial denial was unjustified.
Regulatory and Legislative Responses to Cancer Treatment Denials
Recognition of the cancer treatment denial crisis has led to state-level legislation and regulatory oversight. Some states have implemented laws requiring expedited review processes specifically for cancer treatments, recognizing that the standard 30-day appeal timeline is incompatible with the rapid progression of many cancers. Federal regulations increasingly scrutinize insurance company denial practices in oncology, and some medical boards have begun investigating whether systematic denials constitute a pattern of unprofessional conduct.
Looking forward, the convergence of patient advocacy, class action litigation, and regulatory pressure is beginning to shift insurer behavior. Some major insurance companies have modified their policies to reduce immunotherapy denials and streamline approval for standard-of-care cancer treatments. However, the pace of change remains slow relative to the urgency of patient need, and disparities persist—patients with better health literacy, access to experienced oncologists who know how to appeal, and financial resources to pursue litigation are more likely to overcome denials than vulnerable populations.
Conclusion
Cancer treatment denials represent a systemic problem within the U.S. healthcare system, affecting one in three cancer patients and creating delays that can alter disease progression. When insurers deny immunotherapy, radiation therapy, genetic testing, or other proven cancer treatments, they force patients into a choice between accepting the denial, appealing through time-consuming processes with uncertain outcomes, or paying out of pocket. The data shows that many denials—46% of genetic testing denials, for example—are overturned on appeal, suggesting the initial denials may be inappropriate, yet fewer than 1% of patients pursue appeals.
If you or a loved one has faced a cancer treatment denial, understanding your rights is essential. You may have grounds to appeal through your insurance company’s independent medical review process, pursue a complaint with your state’s insurance commissioner, or join a class action lawsuit challenging systematic denial practices. Consulting with a patient advocate, your oncology team, or an attorney experienced in insurance law can help you navigate these options. Cancer treatment should not be delayed by insurance company gatekeeping—patients deserve access to treatments their physicians recommend based on current medical evidence.